Newborn infants with respiratory distress who fail to respond to surfactant treatment receive a second dose of surfactant. The effect of this strategy on the distribution of surfactant to the lung is unknown. We therefore investigated the distribution of the first (100 mglkg body wcight) and second dose (50 mgikg body weight) of surfactant (Alveofact) in lung-lavaged rabbits (iz = 6). We used I4'Ce-and "'3~n-labeled microspheres that were mixed with the first and second dose of surfactant, respectively. Arterial PoZ increased from 5.7 % 1.1 to 10.6 2 2.0 kPa ( p < 0.05) (mean i SD) after the first and from 20.1 i 3.8 to 30.1 i 2.5 kPa ( p < 0.05) after the second dose. Thereafter the rabbits were killed, and the lungs were cut into 200 pieces. The radioactivity of Ce and Rn microspheres was measured and distribution histograms were obtained. Histograms of the first, second, and the total dose of surfactant showed similar nonuniform distribution. Correlation coefficients of the Ce and Rn radioactivity in the different lung lobes widely ranged per lung lobe per rabbit. In addition, the percentage of the number of lung pieces that Exogenous surfactant therapy has been shown to be beneficial in the treatment of premature infants with RDS. Collaborative studies, using either synthetic, natural, or modified surfactant, given either as prophylaxis or as rescue therapy, have shown decreases both in pulmonary morbidity and neonatal mortality (1-9). However, not all patients benefit from surfactant treatment. Some studies have reported that 22% of surfactant-treated infants failed to respond, and 11% responded only transiently (6, 10, 11). As it was hypothesized that surfactant deficiency was responsible for the relapse, it was suggested that patients who showed deterioration after the initial response to surfactant treatment should be retrcated. Some investigators advocate applying a multiple-dose treatment strategy (12-15). It has been shown that a multiple-dose treatment of surfactant reduced morbidity and mortality in patients with severe RDS. Receivcd Pcbruary 17, 1994; acccpled October 11, 1994 received an amount of surfactant that was less than the calculated endogenous surfactant pool decreased from 12.5 ? 3.2% to 8.5 i-3.0% ( p < 0.05) after the first and second dose, respectively. This indicates that the second dose was directed both to areas that initially received surfactant and to areas that were still surfactantdeficient. The surfactant-deficient areas were aerated after this second dose, resulting in a further rise in Po,. We conclude that a second dose of surfactant does not lead to homogeneous distribution of surfactant but does result in a significant rise in Po, that is probably due to increased aeration after the second dose of surfactant, which may be partially related to an additional recruitment of alveoli after the second dose of surfactant. Recently, we have shown that exogenous surfactant is distributed to the lung in a nonuniform way, and we speculate that an inhomogeneous distribution probably promotes relapse in some patients (16). At present, it is not known how the second dose is distributed to the lung. Is the surfactant directed to areas where surfactant was deposited initially or to areas of the lung that did not receive surfactant? The aim of this study was therefore to investigate whether a second dose of surfactant promotes uniform distribution to the lung. This may explain the improved outcome in patients after multiple dose treatment.
Exogenous surfactant therapy has been shown to be beneficial in the treatment of premature infants with RDS. Collaborative studies, using either synthetic, natural, or modified surfactant, given either as prophylaxis or as rescue therapy, have shown decreases both in pulmonary morbidity and neonatal mortality (1-9). However, not all patients benefit from surfactant treatment. Some studies have reported that 22% of surfactant-treated infants failed to respond, and 11% responded only transiently (6, 10, 11) . As it was hypothesized that surfactant deficiency was responsible for the relapse, it was suggested that patients who showed deterioration after the initial response to surfactant treatment should be retrcated. Some investigators advocate applying a multiple-dose treatment strategy (12) (13) (14) (15) . It has been shown that a multiple-dose treatment of surfactant reduced morbidity and mortality in patients with severe RDS.
received an amount of surfactant that was less than the calculated endogenous surfactant pool decreased from 12.5 ? 3.2% to 8.5 i-3.0% ( p < 0.05) after the first and second dose, respectively. This indicates that the second dose was directed both to areas that initially received surfactant and to areas that were still surfactantdeficient. The surfactant-deficient areas were aerated after this second dose, resulting in a further rise in Po,. We conclude that a second dose of surfactant does not lead to homogeneous distribution of surfactant but does result in a significant rise in Po, that is probably due to increased aeration after the second dose of surfactant, which may be partially related to an additional recruitment of alveoli after the second dose of surfactant. Recently, we have shown that exogenous surfactant is distributed to the lung in a nonuniform way, and we speculate that an inhomogeneous distribution probably promotes relapse in some patients (16). At present, it is not known how the second dose is distributed to the lung. Is the surfactant directed to areas where surfactant was deposited initially or to areas of the lung that did not receive surfactant? The aim of this study was therefore to investigate whether a second dose of surfactant promotes uniform distribution to the lung. This may explain the improved outcome in patients after multiple dose treatment.
METHODS
Animals. In six Chincilla rabbits, weighing 2.5 5 0.3 kg (mean +-SD), severe respiratory failure was induced according to the protocol that we described previously (17) . In short, the rabbits were anesthetized with sodium pentobarbital (Nembutal, Abbot Laboratories, North Chicago, IL), 30 mglkg body weight, and placed in the supine position on a heated mattress. After intubation by means of a tracheostomy, the rabbits were paralyzed with pancuronium bromide (Pavulon, Organon Technics, Oss, The Netherlands), 0.1 mg.kg body weight, and artificially ventilated (Amsterdam Infant Ventilator MK 111, Hoek Loos Co., Schiedam, The Netherlands) with 100% oxygen and in a minute volume of 400 mL.kg body weight. Respiratory rate was set at a frequency of 60lmin with an inspiration time of 40%. A catheter was introduced into the left carotid artery to measure the arterial blood pressure and to obtain samples for blood gas analysis. The lungs were subsequently lavaged five times with 35 mL of normal saline (38°C) per kg of body weight. During this procedure the instillation of normal saline was stopped when the intratracheal pressure reached 3922.4 Pa (40 cm H,O). The rabbits were allowed to recover from each lavage for a 5-min period. During the lavage procedure the level of the PEEP was stepwise increased to 980.6 Pa (10 cm H,O). Fifteen minutes after the lung lavage procedure, the PEEP was lowered to 490.3 Pa (5 cm H,O).
Surfactant treatment. In all rabbits, two doses of bovine surfactant (Alveofact, 45 g/L, Thomae GmbH, Biberach, Germany) were endotracheally instilled. The first surfactant dose of 100 mg.kg body weight was administered 30 min after the last lung lavage, and the second surfactant dose of 50 mg.kg body weight was administered 2 h later. The time interval of 2 h was chosen arbitrarily.
To study the distribution of the two surfactant doses separately, 1.5 Bq of 14'ce-labeled microspheres with a diameter of 15 X 10F6 m (DuPont-New England Nuclear, Hertogenbosch, The Netherlands) were mixed with the first surfactant dose, and 1.5 Bq of lo3~n-labeled microspheres with a diameter of 15 X 10-% (DuPont-New England Nuclear) were mixed with the second surfactant dose. Each animal received approximately 3 X lo4 Bq of radioactivity. Each surfactant instillation was preceded by adding the microspheres to the surfactant and by gently stirring to mix the microspheres with the surfactant. Fifteen minutes after the PEEP was decreased to 490.3 Pa (5 cm H,O), the artificial ventilation was interrupted, and the surfactant was immediately instilled through a side lumen of the tube in approximately 45 s. After the instillation, the side lumen of the tube was flushed with 1.5 mL of 0.9% NaCl to remove the residue of the surfactant, and then the artificial ventilation was resumed. During the procedure the supine position of the rabbits was unaltered. The same surfactant instillation procedure was repeated after 2 h. The rabbits were ventilated for a period of 15 min after the second dose of surfactant to ensure spreading of the surfactant in the same way as was done in our previous surfactant distribution study (16) .
Processing of the lungs. Fifteen minutes after the second surfactant dose, the rabbits were killed with an overdose of pentobarbital. The lungs were processed according to the protocol that we described previously (16). In short, the lungs were removed from the chest, separated into lobes, and frozen in liquid nitrogen. The frozen upper, middle, and lower lobes of the right lung were each cut into 33 pieces, the left upper lobe into 41 pieces, and the left lower lobe into 60 pieces. Each piece of lung tissue was weighed on an analytical balance with a resolution of 0.1 mg (Mettler H35, Mettler-Toledo AG, Ziirich, Switzerland). The radioactivity of the 141ce-and lo3~n-labeled microspheres was measured.
The distribution of the first surfactant dose was studied by the 14'ce radioactivity, the second surfactant dose by 1 " 3~n radioactivity, and the total distribution by adding both the I4'ce and the I0%n radioactivity. To assess the distribution of the endotracheally instilled surfactant over the 200 different lung pieces, the radioactivity was expressed as counts/min/mg of lung tissue in each piece. Then the mean counts/min/mg of all the lung pieces was determined for every rabbit, and in each piece of lung tissue the ratio of the actual counts/min/mg and the mean counts/min/mg were calculated. In this way, a normalized value for the radioactivity per mg was obtained for every piece of lung tissue. We grouped the normalized values in distribution intervals of 10%. Histograms were obtained plotting the number of lung pieces in the 10% distribution intervals. Pieces with a normalized value of <0.1 or >2.0 were grouped at the extremes of the distribution intervals. In this way histiograms were obtained for the distribution of the first, second, and total dose, respectively. To compare the distribution in the different lobes, we calculated the percentage of pieces with a normalized value between arbitrarily chosen limits of 0.8 and 1.2. A higher percentage of lung pieces in this distribution interval represents a more homogeneous distribution of the administered surfactant.
To assess the relationship between the distribution of the first and second surfactant dose in each lobe, the radioactivity of Ce was plotted against the radioactivity of Rn.
To obtain a quantitative impression of the amount surfactant that the different lung pieces received, we counted the number of lung pieces that received less surfactant than the calculated endogenous surfactant pool. The endogenous surfactant pool for adult rabbits is approximately 10 mg.kg body weight (18). Using the following formula, the amount of endogenous surfactant per lung piece can be calculated:
Amount of endogenous surfactant = weight of lung piece X body weight X 10. total lung weight The amount of exogenous surfactant received per lung piece after the first and second dose can be calculated by using the following formulas:
Amount of exogenous surfactant (first dose) = I4'Ce radioactivity lung piece 14'Ce radioactivity total surfactant dose X body weight X 100, Amount of exogenous surfactant (first + second dose) = (14'Ce + "%I) radioactivity lung piece (14'Ce + lo3Rn) radioactivity total surfactant dose X body weight X 150.
Measurement of blood gases.
Blood samples for the determination of arterial Po,, Pco,, and pH were obtained from the left carotid artery. Samples were taken before and after the lung lavage procedure. 
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Ce Figure 1 . Normalized distribution of exogenous surfactant for rabbits with severe respiratory failure treated with two doses of surfactant. All valucs were calculated as described in "Methods" and are expressed as mean number of pieces in each 10% distribution interval. A normalized value of 1.0 represents a uniform distribution. The distribution histograms of the first (A), second (B), and total dose (C) of surfactant showed a similar pattern of nonuniform distribution. A large number of lung pieces received either a small amount of surfactant (normalized value <0.1) or a large amount of surfactant (normalized value >2.0). The number of pieces in the distribution interval <0.1 is decreased for the total dose when compared with the first dose. areas will have a surfactant level that is higher than the cutoff valucs of the endogenous surfactant pool. In this study, using our technique, it is impossible to discriminate whether the decrease in the percentage of lung pieces is an effect of distribution or of a higher dose. However, based on the other results, the correlation between the Ce and Rn microspheres, the second rise in arterial Po2, we think that the decrease is most likely a distribution effect. It is currently assumed that the optimal clinical effect of surfactant therapy will occur when the endotracheally instilled surfactant is distributed in an uniform way throughout the lung. However, as yet, little is known of the distribution of surfactant after administration, particularly in the clinical situation. Invcstigators have tried to study the initial distribution of exogenous surfactants in newborns with RDS, but both studies were unable to assess the distribution at the alveolar level (20, 21) . W e therefore investigated whether the instillation of a second dose of surfactant would promote a uniform distribution throughout the lung. In clinical practice, multiple doses of surfactant are administered because of a relapse in lung function. It has been shown in some studies that the outcome in tcrms of morbidity and mortality in patients with severe RDS was favorable after a multiple-dose treatment (12) (13) (14) (15) (12) demonstrated that multiple doses of surfactant given after diagnosis of RDS in premature infants weighing 600-1750 g reduced mortality and morbidity. We had hypothcsizcd that a more uniform distribution of surfactant would be achieved after multiple dosc treatment, and this would contribute to a more favorable outcome in RDS patients. However, in our study the instillation of a second dose did not result in a uniform distribution of surfactant.
In conclusion, we have demonstrated that a second dose of surfactant does not promote a uniform distribution to the lung but does result in a significant rise in arterial Po,. The second dose is most likely directed to lung parts that initially received surfactant as well as to areas that did not receive surfactant with the first dosc. We assume that thc surfactant-deficient areas wcrc aerated after this second dose, rcsulting in improved oxygenation.
